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Background: Thrombocytopenia has been observed after both surgical aortic valve replacement (SAVR) and TAVR but its determinants, sequelae 
and relative magnitude have been poorly elucidated. We sought to investigate thrombocytopenia post Transcatheter Aortic Valve Replacement (TAVR) 
and to contextualize its magnitude and clinical significance.
methods: Quantitative platelet responses were compared in TAVR and SAVR. An Edwards-Sapien TAVR population was studied for the determinants 
and outcomes of major thrombocytopenia (defined as platelet count < 100 x 109/L). Changes in platelets were studied in 246 patients undergoing 
TAVR and a similar population of 57 cases undergoing SAVR (US PARTNER IA trial surgical cohort) in a single center.
results: An early drop in platelets was seen on the day of intervention. The drop day 1 post procedure was similar but slightly greater with SAVR 
vs TAVR. In SAVR and TAVR, the platelet counts continued to drop, reaching a nadir of approximately 50-60% of the baseline platelet count at day 
2-3. Platelet numbers started to recover after day 5. After TAVR (n=246), early major thrombocytopenia (by nadir count) occurred in 37% of patients 
but was not significantly related to major bleeding (OR 0.89, 95% CI 0.51-1.60, p=0.69) or risk of stroke (HR 0.61, 95% CI 0.16-2.20, p=0.45). 
There was a non-significant trend to greater acute kidney injury (OR 1.76, 95% CI 0.95-3.26, p=0.073) and mortality (HR 1.47, 95% CI 0.98-2.22, 
p=0.065) with early major thrombocytopenia. Major thrombocytopenia was persistent in 7.7% of patients and persistent major thrombocytopenia 
was independently associated with mortality in multivariable analysis (HR 3.65, 95% CI 1.63-8.16, p=0.002).
conclusions: Post-TAVR thrombocytopenia is a common phenomenon and its magnitude appears similar to that seen after SAVR. It is most often 
transient, not associated with adverse sequelae and should be managed in an expectant fashion. However, when persistent, thrombocytopenia is 
associated with a poor clinical outcome and merits detailed evaluation.
